ANTX
Price
$1.38
Change
+$0.09 (+6.98%)
Updated
Sep 18, 12:09 PM (EDT)
Capitalization
34.98M
49 days until earnings call
IONS
Price
$61.59
Change
+$0.42 (+0.69%)
Updated
Sep 18, 01:28 PM (EDT)
Capitalization
9.77B
42 days until earnings call
Interact to see
Advertisement

ANTX vs IONS

Header iconANTX vs IONS Comparison
Open Charts ANTX vs IONSBanner chart's image
AN2 Therapeutics
Price$1.38
Change+$0.09 (+6.98%)
Volume$800
Capitalization34.98M
Ionis Pharmaceuticals
Price$61.59
Change+$0.42 (+0.69%)
Volume$459
Capitalization9.77B
ANTX vs IONS Comparison Chart in %
Loading...
ANTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANTX vs. IONS commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANTX is a StrongBuy and IONS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (ANTX: $1.29 vs. IONS: $61.17)
Brand notoriety: ANTX and IONS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANTX: 112% vs. IONS: 64%
Market capitalization -- ANTX: $34.98M vs. IONS: $9.77B
ANTX [@Biotechnology] is valued at $34.98M. IONS’s [@Biotechnology] market capitalization is $9.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANTX’s FA Score shows that 1 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).

  • ANTX’s FA Score: 1 green, 4 red.
  • IONS’s FA Score: 0 green, 5 red.
According to our system of comparison, ANTX is a better buy in the long-term than IONS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANTX’s TA Score shows that 6 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s).

  • ANTX’s TA Score: 6 bullish, 4 bearish.
  • IONS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ANTX is a better buy in the short-term than IONS.

Price Growth

ANTX (@Biotechnology) experienced а +4.88% price change this week, while IONS (@Biotechnology) price change was -4.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was +6.08%, and the average quarterly price growth was +34.58%.

Reported Earning Dates

ANTX is expected to report earnings on Nov 06, 2025.

IONS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+1.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IONS($9.77B) has a higher market cap than ANTX($35M). IONS YTD gains are higher at: 74.971 vs. ANTX (-6.522). ANTX has higher annual earnings (EBITDA): -39.13M vs. IONS (-170.69M). IONS has more cash in the bank: 2.29B vs. ANTX (62.9M). IONS has higher revenues than ANTX: IONS (944M) vs ANTX (0).
ANTXIONSANTX / IONS
Capitalization35M9.77B0%
EBITDA-39.13M-170.69M23%
Gain YTD-6.52274.971-9%
P/E RatioN/AN/A-
Revenue0944M-
Total Cash62.9M2.29B3%
Total DebtN/A1.42B-
FUNDAMENTALS RATINGS
ANTX vs IONS: Fundamental Ratings
ANTX
IONS
OUTLOOK RATING
1..100
2585
VALUATION
overvalued / fair valued / undervalued
1..100
11
Undervalued
95
Overvalued
PROFIT vs RISK RATING
1..100
10082
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
4736
P/E GROWTH RATING
1..100
10062
SEASONALITY SCORE
1..100
5650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ANTX's Valuation (11) in the Managed Health Care industry is significantly better than the same rating for IONS (95) in the Biotechnology industry. This means that ANTX’s stock grew significantly faster than IONS’s over the last 12 months.

IONS's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as ANTX (100) in the Managed Health Care industry. This means that IONS’s stock grew similarly to ANTX’s over the last 12 months.

IONS's SMR Rating (98) in the Biotechnology industry is in the same range as ANTX (98) in the Managed Health Care industry. This means that IONS’s stock grew similarly to ANTX’s over the last 12 months.

IONS's Price Growth Rating (36) in the Biotechnology industry is in the same range as ANTX (47) in the Managed Health Care industry. This means that IONS’s stock grew similarly to ANTX’s over the last 12 months.

IONS's P/E Growth Rating (62) in the Biotechnology industry is somewhat better than the same rating for ANTX (100) in the Managed Health Care industry. This means that IONS’s stock grew somewhat faster than ANTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANTXIONS
RSI
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
67%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
69%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
67%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 16 days ago
64%
Declines
ODDS (%)
Bearish Trend 10 days ago
83%
Bearish Trend 4 days ago
67%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
71%
Aroon
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
ANTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VTSNX158.36N/A
N/A
Vanguard Total Intl Stock Index I
LAIDX9.93N/A
N/A
Lord Abbett International Value I
LSIFX158.16N/A
N/A
ClearBridge Growth IS
BDHKX8.97N/A
N/A
BlackRock Dynamic High Income K
GUSYX20.49N/A
N/A
Grandeur Peak US Stalwarts Institutional

ANTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANTX has been loosely correlated with ROIV. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ANTX jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANTX
1D Price
Change %
ANTX100%
+0.78%
ROIV - ANTX
34%
Loosely correlated
+7.72%
PASG - ANTX
32%
Poorly correlated
-2.89%
PHAR - ANTX
28%
Poorly correlated
+5.04%
IONS - ANTX
27%
Poorly correlated
-0.24%
REGN - ANTX
27%
Poorly correlated
+1.82%
More